1. Market Research
  2. > Pathology
Customer Support

Talk to Ahmad

+1 718 618 4302

Companies

  • All
    • Roche Group
About 200 reports for Lymphoma (page 1)

Purchase Reports From Reputable Market Research Publishers

Vaginal Cancer - Pipeline Review, H1 2020

  • $ 2000
  • May 2020
  • 381 pages

It is in Phase I stage of development for diffuse large B cell lymphoma and high-grade B cell lymphoma.

  • Lung Cancer
  • Lymphoma
  • Sexually Transmitted Disease
  • United States
  • Roche Group

NHL: Diffuse large Bcell lymphoma

  • $ 5000
  • May 2016
  • 219 pages

Immunophenotyping also needs to be robust enough to distinguish the disease from other lymphomas which resemble DLBCL in morphology, such as mantle cell lymphoma and Burkitt' s lymphoma.

  • Cancer
  • Lymphoma
  • Monoclonal Antibody
  • Therapy
  • Roche Group

NHL: Follicular lymphoma

  • $ 5000
  • April 2016
  • 252 pages

NHL: Follicular lymphoma Disease Coverage | Treatment: Follicular Lymphoma practices.

  • Healthcare
  • Lymphoma
  • Monoclonal Antibody
  • Therapy
  • Roche Group

NHL: Mantle cell lymphoma

  • $ 5000
  • April 2016
  • 214 pages

Lymphoma Association (2016) Mantle cell lymphoma.

  • Immunotherapy
  • Lymphoma
  • Monoclonal Antibody
  • Therapy
  • Roche Group

Chronic Lymphocytic Leukemia - Competitive Landscape to 2030

  • $ 3495
  • May 2020
  • 55 pages

Lung Cancer Breast Cancer Leukemia Lymphoma Non-Small Cell Lung...

  • Leukemia
  • Lymphoma
  • AbbVie Inc.
  • AstraZeneca PLC
  • Roche Group

Vaginal Cancer - Pipeline Review, H2 2019

  • $ 2000
  • December 2019
  • 351 pages

It is in Phase I stage of development for diffuse large B cell lymphoma and high-grade B cell lymphoma.

  • Cancer
  • Lung Cancer
  • Lymphoma
  • United States
  • Roche Group

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2020

  • $ 2000
  • April 2020
  • 403 pages

It is in Phase I stage of development for diffuse large B cell lymphoma and high-grade B cell lymphoma.

  • Lung Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Roche Group

Global Clinical Chemistry Analyzer Market - Opportunities and Forecast (2013-2023)

  • $ 2200
  • March 2019
  • 220 pages

NORTH AMERICA CLINICAL CHEMISTRY ANALYZER MARKET FIGURE ##: NUMBER OF PEOPLE LIVING WITH BLOOD CANCER IN CANADA, 2016 Forms of Blood Cancer Number of Patients Lymphoma ##, ## Leukemia ##, ## Myeloma ##, ## Myelodysplastic Syndromes ##, ## Polycythemia Vera ##, ## Thrombocythemia ##, ## Myelof

  • Clinical Chemistry
  • In Vitro Diagnostics
  • Lymphoma
  • World
  • Roche Group

Global Autoimmune Disease Diagnostic Market (By Disease, Tests Type, Regions), Key Company Profiles - Forecast to 2026

  • $ 1890
  • November 2019
  • 137 pages

lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus diseases.

  • Autoimmune Disease
  • Diagnostics
  • Lymphoma
  • World
  • Roche Group

Global Point of Care Testing Market (By Diagnostics Segment, Mode, End Users, Regions), 100 Company Profiles - Forecast to 2025

  • $ 1690
  • December 2019
  • 218 pages

lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus diseases.

  • Diagnostics
  • Laboratory
  • Lymphoma
  • Point Of Care Testing
  • Roche Group

Age-Related Macular Degeneration: Global Drug Forecast and Market Analysis to 2028

  • $ 10995
  • April 2020
  • 204 pages

Age-Related Macular Degeneration: Global Drug Forecast and Market Analysis to 2028 Summary Age-related macular degeneration (AMD) is an eye condition that is characterized by the gradual deterioration ...

  • Lymphoma
  • Ophthalmology
  • Targeted Therapy
  • Therapy
  • Roche Group

Hemophilia A and B - Global Drug Forecast and Market Analysis to 2028

  • $ 10995
  • August 2019
  • 228 pages

So the CAR T, for example, represents a cure of lymphoma and leukemia.

  • Blood Disease
  • Lymphoma
  • Pathology
  • Therapy
  • Roche Group

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Japan

  • $ 1995
  • April 2019
  • 131 pages

Heart diseases Renal failure Septicemia Diseases of the Malignant liver lymphoma ##. ## ##. ## ##. ## ##. ## ##. ## Heart diseases Renal failure Malignant lymphoma Diseases of the liver Accidents ##. ## ##. ## ##. ## ##. ## ##. ## ##, ## ##, ## ##, ## ##, ## ##, ## Malignant neoplasms Cardiovascular

  • Lymphoma
  • Medical Equipment
  • Pharmaceutical
  • Japan
  • Roche Group

Cancer Biomarkers Market to 2027 - Global Analysis and Forecasts By Biomarker Type; Profiling Technology; Cancer Type; Application and Geography

  • $ 4550
  • October 2019
  • 241 pages

According to the Leukemia and Lymphoma Society, in the United stated it is estimated that ##, ## people living with or in remission from leukemia and ##, ## people are expected to be diagnosed with leukemia and also ##, ## people are expected to die from leukemia in 2019.

  • Biomarker
  • Cancer
  • Lymphoma
  • Market Size
  • Roche Group

Viral Vector & Plasmid DNA Manufacturing Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Product ; Application, and Geography

  • $ 4550
  • June 2020
  • 140 pages

Moreover, the government approvals of lentiviral vector-based CAR-T cell therapies, which is used for the treatment of Acute Lymphoblastic Leukemia (ALL) and large B cell lymphoma, have attracted considerable attention from users.

  • Biopharmaceutical
  • Gene Therapy
  • Lymphoma
  • Medical Biotechnology
  • Roche Group

Global Orphan Drugs Market: Industry Analysis & Outlook (2018-2022)

  • $ 1000
  • July 2018
  • 79 pages

Celgene also gains full global rights to JCAR## (lisocabtagene maraleucel; liso-cel), a CD-## targeted CAR-T therapy currently in pivotal trials for relapsed and/ or refractory diffuse large B-cell lymphoma (DLBCL).

  • Lymphoma
  • Therapy
  • World
  • Bristol-Myers Squibb Company
  • Roche Group

Potential Pipeline Disruptors

  • $ 4200
  • May 2017
  • 120 pages

FOLLICULAR LYMPHOMA TENDS TO BE INDOLENT AND DIFFUSE LYMPHOMA TENDS TO BE AGGRESSIVE.

  • Lymphoma
  • Monoclonal Antibody
  • Targeted Therapy
  • Therapy
  • Roche Group

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Russia

  • $ 1995
  • April 2020
  • 133 pages

Product Discontinuations: Weakness GSK discontinued the global development of GSK-##, which was in Phase I clinical development for relapsed or refractory small-cell lung cancer; and GSK- ##, which was in Phase I trials for follicular lymphoma, diffuse large B-cell

  • Lymphoma
  • Medical Equipment
  • Pharmaceutical
  • Russia
  • Roche Group

Global Liquid Biopsy Market - Opportunities and Forecast (2017-2024)

  • $ 1800
  • October 2019
  • 200 pages

Liquid Biopsy Market ##. ## ##. ## ##. ## ##. ## ##. ## Source: American Cancer Society Digestive System Respiratory System Skin Genital System Breast Urinary System Endocrine System Lymphoma Others 2014 2015 2016 2017 2018 ##. ##% ##. ##% ##. ##% ##. ##% ##. ##% ##. ##% ##. ##% ##. ##% ##. ##% Fig

  • Biotech Diagnostics
  • Cancer
  • Genetic Testing
  • Lymphoma
  • Roche Group

Global CML Market Report - 2022

  • $ 3849
  • June 2018
  • 82 pages

Imatinib mesylate is licensed as a firstline treatment for adults with chronic-phase Ph+ CML, and for the management of GIST, and as salvage therapy for Ph+ acute lymphoblastic lymphoma.

  • Lymphoma
  • Therapy
  • Incyte Corporation
  • Merck & Co., Inc.
  • Roche Group
View report >

Pharmaceutical Markets

  • October 2017
  • 19 pages

For chronic lymphocytic leukaemia (CLL), rituximab-refractory follicular lymphoma and previously untreated advanced follicular lymphoma.

  • Lymphoma
  • Pharmaceutical
  • United States
  • Demand
  • Roche Group

Therapy Market in Europe February 2019

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on